

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884¹

PATENT OWNER'S UPDATED EXHIBIT LIST

¹ IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

Updated Exhibit List for *Inter Partes* Review of U.S. Patent No. 11,253,572

Exhibit No.	Exhibit Description
2001	Expert Declaration of Richard Manning, Ph.D., <i>Mylan Pharms. Inc. v. Regeneron Pharms., Inc.</i> , IPR2021-00881, Ex. No. 2052 (Feb. 11, 2022)
2002	EYLEA® Label (rev. Oct. 2014)
2003	Trial Transcript (unsealed portions), <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.)
2004	Press Release, <i>Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration</i> , Regeneron Pharmaceuticals, Inc. (Mar. 27, 2007)
2005	Email from George Yancopoulos to Murray Goldberg re Top Line sum for PR (Mar. 22, 2007)
2006	Interim Analysis of Phase 2 Study of VEGF Trap in AMD patients (Mar. 22, 2007) (Attachment to Ex.2005)
2007	George D. Yancopoulos, VEGF Trap : Scientific Background, BSP / REGN Kick-Off (Feb. 16, 2007)
2008	Email from Kathleen Lawrence re Decisions & Actions: AMD Ph3 Program Mtg – 4/2/07 (Apr. 2, 2007)
2009	Email from George Yancopoulos to Darlene Jody re Summary of issues for call: AMD P3 Planning with enclosed outline attached (Apr. 4, 2007)
2010	Email from Robert Terifay to George Yancopoulos re VGTeye VIEW 430 presentation (Nov. 19, 2010)
2011	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) - VIEW 1 and VIEW 2 – 1-Year Results (Attachment to Ex.2010)
2012	Regeneron Pharmaceuticals, <i>Phase 1 Study of VEFT Trap in Patients With Diabetic Macular Edema</i> , https://clinicaltrials.gov/study/NCT00320814 (last updated Jun. 10, 2011)
2013	Regeneron, <i>Clinical Study Concept - Ophthalmology-Diabetic Macular Edema-Phase 2-IVT-VGFT-OD-0706</i> (updated May 19, 2008)
2014	Diana V. Do et al., <i>One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema</i> , 119 OPHTHALMOLOGY 1658-1665 (Aug. 2012).

Exhibit No.	Exhibit Description
2015	DA VINCI – DME And VEGF Trap-Eye: Investigation of Clinical Impact: One Year Data (Dec. 8, 2010) (attachment to Ex.2024)
2016	Regeneron Pharmaceuticals, <i>DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)] Investigation of Clinical Impact (DA VINCI)</i> , https://clinicaltrials.gov/study/NCT00789477 (last updated Sep. 9, 2014)
2017	Email from Caroline Saxton re Data Review (Feb. 1, 2010)
2018	Regeneron Pharmaceuticals, Inc., <i>VGFT-OD-0706 Week 24 Topline Results</i> (Feb. 1, 2010) (attachment to Ex.2017)
2019	DRAFT – DA VINCI – 6-Month Primary Endpoint (Feb. 1, 2010) (attachment to Ex.2017)
2020	Regeneron Pharmaceuticals, Inc., <i>VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema</i> (Feb. 18, 2010)
2021	Email from Alyson Berliner to Dave Brown re ARVO late breakers (Mar. 1, 2010)
2022	<i>DA VINCI: DME And VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)</i> (Mar. 1, 2010) (Attachment to Ex.2021)
2023	Email from Dave Brown to Alyson Berliner and James Major re ARVO abstract (Mar. 3, 2010)
2024	Email from Caroline Saxton re Slides and tables – DaVinci (Dec. 8, 2010)
2025	U.S. Provisional Patent Application No. 61/434,836 (Jan. 21, 2011)
2026	Mylan Pharmaceuticals Inc.’s Answer, Defenses, and Counterclaims to Plaintiff’s Complaint, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 47 (filed Aug. 25, 2022)
2027	Stipulation and Order Joining Biocon Biologics Inc. as Defendant, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 523 (filed Jun. 5, 2023)
2028	Complaint for Patent Infringement, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 1 (filed Aug. 2, 2022)

Exhibit No.	Exhibit Description
2029	Order on Claim Construction, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 427 (filed Apr. 19, 2023)
2030	Scheduling Order, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 87 (filed Oct. 25, 2022)
2031	Regeneron's Stipulation Regarding Summary Judgment and Case Narrowing, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 433 (filed Apr. 27, 2023)
2032	Defendant's Opening Post Trial Brief - Issues Where Defendants Bear the Burden of Proof, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 576 (filed July 7, 2023)
2033	Order Setting Briefing Schedule, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 514 (filed May 30, 2023)
2034	Transcript of the Status Conference held on Sept. 28, 2022, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 90 (filed Nov. 2, 2022)
2035	Email from George Yancopoulos re DME Phase 2 – ALL TABLES (Feb. 2, 2010)
2036	DME Target Product Profile - VEGF Trap-Eye (Sept. 26, 2007)
2037	Clinical Development & Regulatory Affairs Weekly Update (Oct. 29, 2010)
2038	Clinical Development & Regulatory Affairs Weekly Update (Dec. 3, 2010)
2039	Email from George Yancopoulos re DME PLANS & FDA meeting pre-discussion (Jan. 9, 2008)
2040	MEMO re Guidance From Bayer/ REGN Sr. Management Regarding Additional Indications in Ophthalmology from George Yancopoulos to Bayer/REGN Joint Development Group (Mar. 28, 2008)
2041	Action Items by GD Yancopoulos - Bayer/REGN JSC (Feb. 15, 2008)
2042	Email from Yuhwen Soo to George Yancopoulos re Can you send me that slide you made combining the VA curves for View1 & View2 (Nov. 20, 2010)

Exhibit No.	Exhibit Description
2043	Vascular Endothelial Growth Factor (VEGF): Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)—VIEW1 + VIEW 2: 1-Year Results (Nov. 20, 2010) (Attachment to Ex.2042)
2044	Email from Michael Aberman to George Yancopoulos and Leonard Schleifer re Press Release (Nov. 19, 2010)
2045	Regeneron, <i>Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration</i> (Nov. 19, 2010) (Attachment to Ex.2044)
2046	U.S. Food & Drug Administration, <i>22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results</i> (Jan. 2017)
2047	VEGF Trap-Eye in Wet AMD - CLEAR-IT 2: Summary of One-Year Key Results, Presented at 2008 Retina Society Meeting, Scottsdale, Arizona (Sep. 28, 2008)
2048	Regeneron Pharmaceuticals, Inc., <i>A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)</i> (Issued Jan. 28, 2009)
2049	Appendix to Heier et al., <i>Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration</i> , 119 OPTHALMOLOGY 2537 (2012)
2050	<i>Retinal Physician Symposium Covers Broad Range of Topics</i> , Retinal Physician (Sept. 1, 2006), https://www.retinalphysician.com/issues/2006/september2006/retinal-physician-symposium-covers-broad-range-of
2051	Prema Abraham et al., <i>Randomized, Double-Masked, ShamControlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 AM. J. OPTHALMOLOGY 315 (2010)
2052	FDA, <i>Step 3: Clinical Research</i> , https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (last accessed Aug. 23, 2023)
2053	Prosecution History of U.S. Patent App. No. 16/159,282 B2
2054	Anant Pai et al., <i>Current concepts in intravitreal drug therapy for diabetic retinopathy</i> , 24 SAUDI J. OPTHALMOLOGY 143 (June 30, 2010)

Exhibit No.	Exhibit Description
2055	David M. Brown et al., <i>Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two phase III Trials</i> , 120 OPTHALMOLOGY 2013 (2013)
2056	Jean-Francois Korobelnik et al., <i>Intravitreal Aflibercept for Diabetic Macular Edema</i> , 121 OPTHALMOLOGY 2247 (2014)
2057	Quan Dong Nguyen et al., <i>Ranibizumab for Diabetic Macular Edema, Results from 2 Phase III Randomized Trials: RISE and RIDE</i> , 119 OPTHALMOLOGY 789 (2012)
2058	Ursula Schmidt-Erfurth et al., <i>Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema</i> . 121 OPTHALMOLOGY 1045 (2014)
2059	Default Protective Order
2060	Declaration of Kira A. Davis in Support of Motion for Admission <i>Pro Hac Vice</i> (“Davis Decl.”)
2061	Declaration of Daralyn J. Durie in Support of Motion for Admission <i>Pro Hac Vice</i> (“Durie Decl.”)
2062 [NEW]	Deposition Transcript of Edward Chaum, M.D., Ph.D. (January 5, 2024)
2063 [NEW]	Declaration of George Yancopoulos, M.D., PH.D. (February 19, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2064 [NEW]	Declaration of Karen Chu (February 19, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2065 [NEW]	Declaration of Michael W. Stewart, M.D. (February 21, 2024)
2066 [NEW]	Declaration of David M. Brown, M.D. (February 21, 2024)
2067 [NEW]	Declaration of Richard Manning, Ph.D. (February 22, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2068 [NEW]	Press Release, Regeneron, <i>Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases</i> (October 18, 2006)
2069 [NEW]	Regeneron/Bayer Alliance, Internal Kick-Off Meeting (November 8, 2006) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2070 [NEW]	Email from Robert Terifay to Leonard Schleifer and George Yancopoulos (March 22, 2007) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2071 [NEW]	Email from Peter Powchik to George Yancopoulos (March 22, 2007)
2072 [NEW]	PowerPoint Presentation (Attachment to Ex.2071) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2073 [NEW]	PowerPoint Presentation (Attachment to Ex. 2074) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2074 [NEW]	Email from George Yancopoulos to Leonard Schleifer (March 22, 2007)
2075 [NEW]	Email from George Yancopoulos to Darlene Jody (April 10, 2007) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2076 [NEW]	CLEAR-IT 3 Clinical Trial Protocol – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2077 [NEW]	Email from Alyson Berliner to Dave Brown (March 1, 2020)
2078 [NEW]	Email from Dave Brown to Alyson Berliner; Robert Vitti; James Major (March 2, 2010)
2079 [NEW]	Draft of document titled DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)
2080 [NEW]	Document titled DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)
2081 [NEW]	Curriculum Vitae of David Mark Brown MD FACS
2082 [NEW]	David M. Brown et al., <i>Ranibizumab versus verteporfin for neovascular age-related macular degeneration</i> , New England Journal of Medicine, 355(14), 1432-1444 (2006)
2083 [NEW]	Philip J. Rosenfeld et al., <i>Ranibizumab for neovascular age-related macular degeneration</i> , New England Journal of Medicine, 355(14), 1419-1431 (2006)

Exhibit No.	Exhibit Description
2084 [NEW]	Press Release, <i>Genentech, Inc. Submits Biologics License Application for FDA Review of Lucentis(TM) In Wet Age-Related Macular Degeneration</i> (Dec. 30, 2005)
2085 [NEW]	Jonathan P. Levine et al., <i>Macular Hemorrhage in Neovascular Age-Related Macular Degeneration After Stabilization with Antiangiogenic Therapy</i> , 29 <i>Retina</i> , 1074-79 (2009)
2086 [NEW]	Irene Barbazetto et al., <i>Dosing Regimen and The Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab</i> , 30 <i>RETINA</i> 1376-85 (2010)
2087 [NEW]	Daniele Cruz, <i>PIER Data Suggest a Need for Tailored Injection Schedule</i> , <i>Ocular Surgery News</i> , (Sept. 1, 2006)
2088 [NEW]	Press Release, Genentech, <i>FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration</i> (June 30, 2006)
2089 [NEW]	Drugs@FDA, Lucentis Label, c. 2006, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf .
2090 [NEW]	Deposition Transcript of Edward Chaum, M.D., Ph.D. Volume 2 (February 2, 2024)
2091 [NEW]	Declaration of Jeffrey Spada (February 20, 2024)
2092 [NEW]	Document Containing Screenshots of Database – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2093 [NEW]	<i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc. et al</i> , No. 22-cv-00061, Dkt. No. 692 (N.D.V.A. Jan. 31, 2024)
2094 [NEW]	Carl D. Regillo et al., <i>Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 <i>AM. J. OPHTHALMOLOGY</i> 315 (2010)
2095 [NEW]	Candelaria Gomez-Manzano et al., <i>VEGF Trap induces antiglioma effect at different stages of disease</i> , <i>Neuro-oncology</i> , 10(6), 940-945 (2008)
2096 [NEW]	Curriculum Vitae of Michael W. Stewart, MD
2097 [NEW]	Geeta A. Lalwani et al., <i>A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular</i>

Exhibit No.	Exhibit Description
	<i>degeneration: year 2 of the PrONTO Study</i> , American journal of ophthalmology, 148(1), 43-58 (2009)
2098 [NEW]	F.G. Holz et al., SUSTAIN Study Group, <i>Safety and Efficacy of Ranibizumab Treatment in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Results of the SUSTAIN Study</i> , Investigative Ophthalmology & Visual Science, 50(13), 3095-3095 (2009)
2099 [NEW]	RESERVED
2100 [NEW]	Eylea® Label (2016)
2101 [NEW]	Jean-Francois Korobelnik et al., <i>Intravitreal Aflibercept for Diabetic Macular Edema</i> , 121 OPTHALMOLOGY 2247 (2014)
2102 [NEW]	LUCENTIS® Label (rev. Aug. 2012)
2103 [NEW]	Prema Abraham et al., <i>Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 AM. J. OPTHALMOLOGY 315-324 (2010)
2104 [NEW]	<i>Retinal Physician Symposium Covers Broad Range of Topics</i> , Retinal Physician (Sept. 1, 2006)
2105 [NEW]	Regeneron Pharmaceuticals, <i>DME and VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)] Investigation of Clinical Impact (DA VINCI)</i> , https://classic.clinicaltrials.gov/ct2/show/study/NCT00789477
2106 [NEW]	Regeneron Press Release, <i>Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication</i> (Dec. 18, 2013)
2107 [NEW]	AVASTIN™ Label (2004)
2108 [NEW]	AVASTIN Approval Letter (February 26, 2004)
2109 [NEW]	Genentech, Inc., <i>A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)</i> , NCT00473330, ClinicalTrials.gov (December 14, 2023), https://www.clinicaltrials.gov/ct2/show/NCT00473330

Exhibit No.	Exhibit Description
2110 [NEW]	Genentech Press Release, <i>FDA Approves Genentech's Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States</i> , (April 17, 2017)
2111 [NEW]	LUCENTIS® Label (2017)
2112 [NEW]	Sarah Whelan, <i>What is Angiogenesis?</i> , Technology Networks (July 6, 2022)
2113 [NEW]	Matthew Dombrow et al., <i>Ocular Angiogenesis: The Science Behind the Symptoms</i> , Retinal Physician (2011)
2114 [NEW]	Joan W. Miller, VEGF: <i>From Discovery to Therapy: The Champalimaud Award Lecture</i> , Translational Vision Science & Technology, 5(2), 9-9 (2016)
2115 [NEW]	Macugen Approval Letter (December 14, 2004)
2116 [NEW]	Press Release, Genentech, <i>FDA Approves Genentech's Lucentis (Ranibizumab Injection) Prefilled Syringe</i> (October 14, 2016)
2117 [NEW]	RESERVED
2118 [NEW]	Press Release, Genentech, <i>Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration</i> (December 30, 2005)
2119 [NEW]	P Mitchell et al., <i>Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials</i> , 94 BRIT. J. OPHTHALMOLOGY 2-13 (2009)
2120 [NEW]	Donald S. Fong et al., <i>Diabetic Retinopathy</i> , Diabetes Care, 27 (10), 2540-2553 (2004).
2121 [NEW]	Early Treatment Diabetic Retinopathy Study Research Group, <i>Early photocoagulation for diabetic retinopathy: ETDRS Report Number 9</i> , Ophthalmology, 98(5), 766-785 (1991)
2122 [NEW]	Diabetic Retinopathy Study Research Group, <i>Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8</i> , Ophthalmology, 88(7), 583-600 (1981)
2123 [NEW]	Ovidiu Musat et al., <i>Diabetic macular edema</i> , Romanian Journal of Ophthalmology, 59(3), 133 (2015)

Exhibit No.	Exhibit Description
2124 [NEW]	Early Treatment Diabetic Retinopathy Study Research Group, <i>Photocoagulation for Diabetic Macular Edema, ETDRS report Number 1, Arch Ophthalmol</i> , 103(12), 1796-1806 (1985)
2125 [NEW]	Anita Prasad, The DRCR Network Aids DR Treatment, <i>Review of Ophthalmology</i> (2006)
2126 [NEW]	Pedro Romero-Aroca et al., <i>Laser treatment for diabetic macular edema in the 21st century</i> , <i>Current Diabetes Reviews</i> , 10(2), 100-112 (2014)
2127 [NEW]	Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, <i>Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1</i> , <i>Archives of Ophthalmology</i> , 117(10), 1329-1345 (1999)
2128 [NEW]	FDA, <i>Step 3: Clinical Research</i> , https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (last accessed Aug. 23, 2023)
2129 [NEW]	Press Release, BioSpace, <i>Opko Health, Inc. Announces Update on Phase III Clinical Trial of Bevasiranib; Company Decided to Terminate Clinical Study</i> (March 6, 2009)
2130 [NEW]	Press Release, Opko Health, <i>Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD</i> (July 11, 2007)
2131 [NEW]	Press Release, Opko Health, <i>OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials</i> (December 6, 2007)
2132 [NEW]	Dhyana Sharma et al., <i>Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases</i> , <i>Investigative Ophthalmology & Visual Science</i> , 64(5), 28-28 (2023)
2133 [NEW]	How to Read a Study Record, ClinicalTrials.gov, available at https://clinicaltrials.gov/study-basics/how-to-read-study-record#record-history-tab (last updated Jan. 9, 2024).
2134 [NEW]	Archived Webpage Re: Clinical Trial No. NCT00473330
2135 [NEW]	Sarah Whelan, <i>What is Angiogenesis?</i> , Technology Networks (July 6, 2022)
2136 [NEW]	Thomas H. Adair & Jean-Pierre Montani, <i>Angiogenesis</i> , Morgan & Claypool Life Sciences (2011)

Exhibit No.	Exhibit Description
2137 [NEW]	Michael J. Tolentino et al., <i>Intravitreal Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate</i> , Ophthalmology, 103(11), 1820-1828 (1996)
2138 [NEW]	David M. Brown et al., <i>Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial</i> , JAMA Ophthalmology, 139(9), 946-955 (2021)
2139 [NEW]	Jeffrey S. Heier et al., <i>Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies</i> , Ophthalmology, 123(11), 2376-2385 (2016)
2140 [NEW]	Drugs@FDA, Eylea label, 2/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s075lbl.pdf
2141 [NEW]	American Society of Retina Specialists, “2015 Preferences and Trends (PAT) Survey,” c. 2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2142 [NEW]	American Society of Retina Specialists, “2016 Preferences and Trends (PAT) Survey,” c. 2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2143 [NEW]	Regeneron, “DME Market Assessment,” 8/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2144 [NEW]	Regeneron, “Q2 2020 Performance Update,” 7/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2145 [NEW]	U.S. Patent Provisional Application No. 61/432,245
2146 [NEW]	U.S. Patent No. 11,730,794 B2
2147 [NEW]	American Society of Retina Specialists, "2009 Preferences and Trends Membership Survey," c. 2009 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2148 [NEW]	Beovu label, 10/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf

Exhibit No.	Exhibit Description
2149 [NEW]	Beovu label, 12/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf
2150 [NEW]	Centers for Disease Control and Prevention, <i>Vision Loss: A Public Health Problem</i> , 12/19/2022, https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm
2151 [NEW]	Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service
2152 [NEW]	Drugs.com Website, Eylea FDA Approval History, https://www.drugs.com/history/eylea.html (accessed 1/16/2024)
2153 [NEW]	Eylea label, 5/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf
2154 [NEW]	Eylea label, 9/2012, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf
2155 [NEW]	Guha, Rahul, Jian Li, and Andrea L. Scott (2009), <i>The Economics of Commercial Success in Pharmaceutical Patent Litigation</i> , Landslide 1(5) (2009)
2156 [NEW]	Lucentis label, 3/2018, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf
2157 [NEW]	Lucentis label, 6/2010, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf
2158 [NEW]	Manning, Richard, et al. (2015), <i>Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?</i> , International Journal of the Economics of Business 22(2): 231–243 (2015)
2159 [NEW]	NCI, Second-Line Therapy, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/second-line-therapy (accessed 1/16/2024)

Exhibit No.	Exhibit Description
2160 [NEW]	Regeneron Press Release, <i>Eylea (Aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)</i> , 7/29/2014
2161 [NEW]	Regeneron Website, History, https://www.regeneron.com/about/history (accessed 1/15/2024).
2162 [NEW]	Regeneron, “DME Market Assessment Q1 2015,” 4/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2163 [NEW]	Regeneron, “DME Market Assessment Q1 2016,” 4/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2164 [NEW]	Regeneron, “DME Market Assessment Q1 2017,” 5/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2165 [NEW]	Regeneron, “DME Market Assessment Q1 2018,” 5/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2166 [NEW]	Regeneron, “DME Market Assessment Q2 2015,” 8/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2167 [NEW]	Regeneron, “DME Market Assessment Q2 2016,” 8/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2168 [NEW]	Regeneron, “DME Market Assessment Q2 2017,” 7/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2169 [NEW]	Regeneron, “DME Market Assessment Q2 2018,” 7/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2170 [NEW]	Regeneron, “DME Market Assessment Q3 2015,” 11/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2171 [NEW]	Regeneron, “DME Market Assessment Q3 2016,” 10/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2172 [NEW]	Regeneron, “DME Market Assessment Q3 2017,” 10/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2173 [NEW]	Regeneron, “DME Market Assessment Q4 2014,” 1/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2174 [NEW]	Regeneron, “DME Market Assessment Q4 2015,” 2/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2175 [NEW]	Regeneron, “DME Market Assessment Q4 2016,” 1/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2176 [NEW]	Regeneron, “DME Market Assessment Q4 2017,” 2/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2177 [NEW]	Regeneron, “DME Market Assessment Wave 3, Q3 2014,” 11/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2178 [NEW]	Regeneron, “DME Market Assessment, Benchmark Wave,” 11/8/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2179 [NEW]	Regeneron, “Physician ATU: Q1 2015,” 4/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2180 [NEW]	Regeneron, “Physician ATU: Q2 2015,” 7/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2181 [NEW]	Regeneron, “Physician ATU: Q3 2014,” 11/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2182 [NEW]	Regeneron, “Physician ATU: Q3 2015,” 11/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2183 [NEW]	Regeneron, “Physician ATU: Q4 2014,” 1/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2184 [NEW]	Regeneron, “Physician ATU: Q4 2015,” 1/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2185 [NEW]	Regeneron, “Physician ATU: Wave 2,” 2/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2186 [NEW]	Regeneron, “Physician ATU: Wave 4,” 8/6/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2187 [NEW]	Regeneron, “Physician ATU: Wave 5,” 11/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2188 [NEW]	Regeneron, “Physician ATU: Wave 6,” 1/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2189 [NEW]	Regeneron, “Physician ATU: Wave 7,” 4/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2190 [NEW]	Regeneron, “Physician ATU: Wave 8,” 8/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2191 [NEW]	Regeneron, “Q1 2019 Performance Update Wet AMD, DME, & MEfRVO,” 5/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2192 [NEW]	Regeneron, “Q1 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 4/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2193 [NEW]	Regeneron, “Q2 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 8/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2194 [NEW]	Regeneron, “Q3 2018 Performance Update Wet AMD, DME, & MEfRVO,” 11/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2195 [NEW]	Regeneron, “Q3 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 11/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2196 [NEW]	Regeneron, “Q3 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 11/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2197 [NEW]	Regeneron, “Q4 2018 Performance Update Wet AMD, DME, & MEfRVO,” 2/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2198 [NEW]	Regeneron, “Q4 2019 Performance Update Wet AMD, DME, & MEfRVO,” 1/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2199 [NEW]	Regeneron, “Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 1/29/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2200 [NEW]	RESERVED
2201 [NEW]	RESERVED
2202 [NEW]	RESERVED
2203 [NEW]	RESERVED
2204 [NEW]	RESERVED
2205 [NEW]	RESERVED
2206 [NEW]	RESERVED
2207 [NEW]	RESERVED
2208 [NEW]	RESERVED
2209 [NEW]	RESERVED
2210 [NEW]	RESERVED
2211 [NEW]	RESERVED
2212 [NEW]	RESERVED
2213 [NEW]	RESERVED

Exhibit No.	Exhibit Description
2214 [NEW]	Regeneron, “US Eylea P&L LTD,” c. 2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2215 [NEW]	Regeneron, “Wet AMD Physician ATU: Q1 2016,” 4/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2216 [NEW]	Regeneron, “Wet AMD Physician ATU: Q1 2017,” 4/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2217 [NEW]	Regeneron, “Wet AMD Physician ATU: Q1 2018,” 5/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2218 [NEW]	Regeneron, “Wet AMD Physician ATU: Q2 2016,” 8/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2219 [NEW]	Regeneron, “Wet AMD Physician ATU: Q2 2017,” 7/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2220 [NEW]	Regeneron, “Wet AMD Physician ATU: Q2 2018,” 7/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2221 [NEW]	Regeneron, “Wet AMD Physician ATU: Q3 2016,” 10/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2222 [NEW]	Regeneron, “Wet AMD Physician ATU: Q3 2017,” 10/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2223 [NEW]	Regeneron, “Wet AMD Physician ATU: Q4 2016,” 1/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2224 [NEW]	Regeneron, “Wet AMD Physician ATU: Q4 2017,” 1/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2225 [NEW]	Regeneron, “Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME,” 9/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2226 [NEW]	Regeneron, ATU Sales Share Data: All Indications, c. 2021

Exhibit No.	Exhibit Description
2227 [NEW]	Regeneron, ATU Sales Share Data: BRVO, c. 2021
2228 [NEW]	Regeneron, ATU Sales Share Data: CRVO, c. 2021
2229 [NEW]	Regeneron, ATU Sales Share Data: DME, c. 2021
2230 [NEW]	Regeneron, ATU Sales Share Data: DR w/o DME, c. 2021
2231 [NEW]	Regeneron, ATU Sales Share Data: Wet AMD, c. 2021
2232 [NEW]	Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2233 [NEW]	Regeneron, Form 10-K, 2020
2234 [NEW]	Susvimo Label, 10/2021, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf
2235 [NEW]	Susvimo Label, 4/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761197s002lbl.pdf
2236 [NEW]	Vabysmo Label, 1/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf
2237 [NEW]	Vabysmo Label, 1/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s001lbl.pdf
2238 [NEW]	Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2239 [NEW]	World Health Organization, "Blindness and Vision Impairment Fact Sheet," 8/10/2023, https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
2240 [NEW]	Declaration of Nathaniel E Frank-White (February 15, 2024)

IPR2023-00884

Date: February 23, 2024

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S UPDATED EXHIBIT LIST was served on the date listed below via email (by agreement) upon the following counsel of record for Petitioners:

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Elliot Choi (*pro hac vice* granted)
Zachariah Summers (*pro hac vice* granted)
Sarah Cork (*pro hac vice* to be applied for)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART
& SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
General Tel: (212) 849-7000
Direct Tel: (212) 849-7322
Fax: (212) 849-7100
Email: raynimrod@quinnemanuel.com
Email: matthewtraupman@quinnemanuel.com
Email: elliotchoi@quinnemanuel.com
Email: zachsummers@quinnemanuel.com
Email: landonsmith@quinnemanuel.com
Email: qe-samsungbioepis@quinnemanuel.com

Paul J. Molino (Reg. No. 45,350)
William A. Rakoczy (*pro hac vice* to be filed)
Deanne M. Mazzochi (Reg. No. 50,158)
Heinz J. Salmen (*pro hac vice* to be filed)
Eric R. Hunt (*pro hac vice* to be filed)
Neil B. McLaughlin (Reg. No. 70,810)
Lauren M. Lesko (*pro hac vice* to be filed)
L. Scott Beall (Reg. No. 52,601)
Thomas H. Ehrich (Reg. No. 67,122)
Steven J. Birkos (Reg. No. 65,300)
Jake R. Ritthamel (*pro hac vice* to be filed)
Rakoczy Molino Mazzochi Siwik LLP

6 West Hubbard Street
Chicago, IL 60654
Telephone: (312) 527-2157
Facsimile: (312) 843-6260
Email: MYL_REG_IPR@rmmslegal.com

Lora Green (Reg. No. 43,541)
Yahn-Lin Chu (Reg. No. 75,946)
Robert Cerwinski (to be admitted *pro hac vice*, pending)
Aviv Zalcenstein (to be admitted *pro hac vice*, pending)
Brigid Morris (to be admitted *pro hac vice*, pending)
Gemini Law LLP
40 W 24th Street, Suite 6N
New York, NY 10010
Tel.: 917-915-8832
Email: lgreen@geminilaw.com
Email: fchu@geminilaw.com
Email: rcerwinski@geminilaw.com
Email: azalcenstein@geminilaw.com
Email: bmorris@geminilaw.com

Dated: February 23, 2024

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287